2024-09-19 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

This report provides a comprehensive analysis of Eli Lilly and Co (LLY) based on the provided data.

**1. Performance Comparison:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) over the observed period. While LLY's cumulative return stands at 875.23%, the S&P 500 only reached 129.06%. This difference translates to a 746.17% gap, representing a 92.59% position in the historical performance range.

**Company Overview:**

Eli Lilly and Co is a leading pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products, including diabetes medications, oncology treatments, and autoimmune disease therapies.

**2. Recent Price Movement:**

* **Closing Price:** $905.34
* **5-day Moving Average:** $921.7
* **20-day Moving Average:** $934.97
* **60-day Moving Average:** $897.78

The current price is below all three moving averages, indicating a possible short-term downtrend. 

**3. Technical Indicators:**

* **RSI:** 35.33
* **PPO:** -0.58

The RSI indicates that LLY is currently in oversold territory, potentially suggesting a buying opportunity. The negative PPO value suggests that the momentum is slightly bearish. 

The **Delta_Previous_Relative_Divergence** of -3.32 indicates a recent short-term downward shift in the stock's relative performance.

The **Expected Return** of 59.87% represents the maximum projected return on investment over the next 5 years, based on current market conditions.

**4. Recent Earnings & Outlook:**

The latest earnings report shows:

| Date       | EPS  | Revenue        |
|------------|------|----------------|
| 2024-08-08 | 3.29 | $11.30 Billion |

The company exceeded analysts' expectations for both EPS and revenue. This indicates strong growth potential for the company and suggests continued positive momentum. 

**5. Overall Analysis:**

Overall, LLY shows strong historical performance, significantly outperforming the market. The recent price action suggests some short-term weakness, but the technical indicators and strong recent earnings report point to potential upside. The company's continued success in developing and marketing innovative pharmaceutical products positions it for continued growth in the future.

**6. Recommendations:**

While the recent price action indicates a potential pullback, the company's strong fundamentals and positive earnings outlook suggest that LLY remains a solid investment opportunity.  Investors may consider accumulating shares at current levels, particularly those with a long-term investment horizon. 

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. It is essential to conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
